Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBR-GAS trial of neoadjuvant gemcitabine + nab-paclitaxel + S-1 for biologically borderline resectable pancreatic cancer
jRCTs061260011Phase 2Recruiting
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel and tegafur in pancreatic cancer (PC). Primary endpoint: 2-year progression-free survival rate. Started May 2026; status: recruiting.
02
Drugs
gemcitabinepaclitaxeltegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs061260011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061260011.